Decreased ITIH5 expression is associated with poor prognosis in primary gastric cancer

Medical Oncology

Volumn 31, Issue 7, 2014, Pages

  Mai, Cong ^a   Zhao, Jing Jing ^a   Tang, Xiao Feng ^b   Wang, Wei ^a   Pan, Ke ^a   Pan, Qiu Zhong ^a   Zhang, Xiao Fei ^a   Jiang, Shan Shan ^a   Zhao, Bai Wei ^a   Li, Yuan Fang ^a   Xia, Jian Chuan ^a   Zhou, Zhi Wei ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

Gastric cancer; Inter trypsin inhibitor heavy chain 5 (ITIH5); Prognostic marker; Survival

Indexed keywords

INTER ALPHA TRYPSIN INHIBITOR; INTER ALPHA TRYPSIN INHIBITOR 5; UNCLASSIFIED DRUG; ITIH5 PROTEIN, HUMAN; LEUKOCYTE ELASTASE INHIBITOR; TUMOR MARKER;

ADULT; ARTICLE; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER STAGING; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH CANCER; SURVIVAL TIME; TUMOR VOLUME; WESTERN BLOTTING; AGED; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; PROGNOSIS; STOMACH NEOPLASMS;

AGED; BLOTTING, WESTERN; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROTEINASE INHIBITORY PROTEINS, SECRETORY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84901899587     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-014-0053-1     Document Type: Article

References (28)

1. Jinawath N, Furukawa Y, Hasegawa S, et al. Comparison of gene-expression profiles between diffuse- and intestinal-type gastric cancers using a genome-wide cDNA microarray. Oncogene. 2004;23(40):6830-44. (Pubitemid 39280016)
2. Li YF, Wang DD, Zhao BW, et al. Poor prognosis of gastric adenocarcinoma with decreased expression of AHRR. PLoS ONE. 2012;7(8):e43555.
3. Tay ST, Leong SH, Yu K, et al. A combined comparative genomic hybridization and expression microarray analysis of gastric cancer reveals novel molecular subtypes. Cancer Res. 2003;63(12):3309-16. (Pubitemid 36735888)
4. Yang XB, Zhao JJ, Huang CY, et al. Decreased expression of the FOXO3a gene is associated with poor prognosis in primary gastric adenocarcinoma patients. PLoS ONE. 2013;8(10):e78158.
5. Wang P, Mai C, Wei YL, et al. Decreased expression of the mitochondrial metabolic enzyme aconitase (ACO2) is associated with poor prognosis in gastric cancer. Med Oncol. 2013;30(2):552.
6. Chen Y, Pan K, Li S, et al. Decreased expression of V-set and immunoglobulin domain containing 1 (VSIG1) is associated with poor prognosis in primary gastric cancer. J Surg Oncol. 2012;106(3):286-93.
7. Miao R, Guo X, Zhi Q, et al. VEZT, a novel putative tumor suppressor, suppresses the growth and tumorigenicity of gastric cancer. PLoS ONE. 2013;8(9):e74409.
8. Kim K, Chun KH, Suh PG, Kim IH. Alterations in cell proliferation related gene expressions in gastric cancer. Crit Rev Eukaryot Gene Expr. 2011;21(3):237-54.
9. Saeki N, Ono H, Sakamoto H, Yoshida T. Genetic factors related to gastric cancer susceptibility identified using a genome-wide association study. Cancer Sci. 2013;104(1):1-8.
10. Veeck J, Chorovicer M, Naami A, et al. The extracellular matrix protein ITIH5 is a novel prognostic marker in invasive node-negative breast cancer and its aberrant expression is caused by promoter hypermethylation. Oncogene. 2008;27(6):865-76. (Pubitemid 351186309)
11. Wei B, Song Y, Zhang Y, Hu M. microRNA-449a functions as a tumor-suppressor in gastric adenocarcinoma by targeting Bcl-2. Oncol Lett. 2013;6(6):1713-8.
12. Himmelfarb M, Klopocki E, Grube S, et al. ITIH5, a novel member of the inter-alpha-trypsin inhibitor heavy chain family is downregulated in breast cancer. Cancer Lett. 2004;204(1):69-77. (Pubitemid 38117195)
13. Oing C, Jost E, Dahl E, Wilop S, Brummendorf TH, Galm O. Aberrant DNA hypermethylation of the ITIH5 tumor suppressor gene in acute myeloid leukemia. Clin Epigenetics. 2011;2(2):419-23.
14. Diarra-Mehrpour M, Bourguignon J, Sesboue R, et al. Human plasma inter-alpha-trypsin inhibitor is encoded by four genes on three chromosomes. Eur J Biochem. 1989;179(1):147-54. (Pubitemid 19097669)
15. Diarra-Mehrpour M, Sarafan N, Bourguignon J, Bonnet F, Bost F, Martin JP. Human inter-alpha-trypsin inhibitor heavy chain H3 gene. Genomic organization, promoter analysis, and gene linkage. J Biol Chem. 1998;273(41):26809-19. (Pubitemid 28471698)
16. Hamm A, Veeck J, Bektas N, et al. Frequent expression loss of Inter-alpha-trypsin inhibitor heavy chain (ITIH) genes in multiple human solid tumors: a systematic expression analysis. BMC Cancer. 2008;8:25.
17. Lu Y, Liu P, Wen W, et al. Cross-species comparison of orthologous gene expression in human bladder cancer and carcinogeninduced rodent models. Am J Transl Res. 2010;3(1):8-27.
18. Pita JM, Banito A, Cavaco BM, Leite V. Gene expression profiling associated with the progression to poorly differentiated thyroid carcinomas. Br J Cancer. 2009;101(10):1782-91.
19. Huang L, Yoneda M, Kimata K. A serum-derived hyaluronan-associated protein (SHAP) is the heavy chain of the inter alpha-trypsin inhibitor. J Biol Chem. 1993;268(35):26725-30. (Pubitemid 23361760)
20. Kobayashi H, Gotoh J, Hirashima Y, Fujie M, Sugino D, Terao T. Inhibitory effect of a conjugate between human urokinase and urinary trypsin inhibitor on tumor cell invasion in vitro. J Biol Chem. 1995;270(14):8361-6.
21. Zhao M, Yoneda M, Ohashi Y, et al. Evidence for the covalent binding of SHAP, heavy chains of inter-alpha-trypsin inhibitor, to hyaluronan. J Biol Chem. 1995;270(44):26657-63.
22. Paris S, Sesboue R, Delpech B, et al. Inhibition of tumor growth and metastatic spreading by overexpression of inter-alpha-trypsin inhibitor family chains. Int J Cancer. 2002;97(5):615-20. (Pubitemid 34087799)
23. Nagini S. Carcinoma of the stomach: a review of epidemiology, pathogenesis, molecular genetics and chemoprevention. World J Gastrointest Oncol. 2012;4(7):156-69.
24. Zouridis H, Deng N, Ivanova T, et al. Methylation subtypes and large-scale epigenetic alterations in gastric cancer. Sci Transl Med. 2012;4(156):156ra140.
25. Miotto E, Sabbioni S, Veronese A, et al. Frequent aberrant methylation of the CDH4 gene promoter in human colorectal and gastric cancer. Cancer Res. 2004;64(22):8156-9. (Pubitemid 39491750)
26. Graff JR, Herman JG, Lapidus RG, et al. E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res. 1995;55(22):5195-9.
27. Bachman KE, Herman JG, Corn PG, et al. Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggest a suppressor role in kidney, brain, and other human cancers. Cancer Res. 1999;59(4):798-802. (Pubitemid 29086729)
28. Shao G, Berenguer J, Borczuk AC, Powell CA, Hei TK, Zhao Y. Epigenetic inactivation of Betaig-h3 gene in human cancer cells. Cancer Res. 2006;66(9):4566-73.